Tags

Type your tag names separated by a space and hit enter

FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.
Virchows Arch. 2014 Nov; 465(5):547-58.VA

Abstract

FGFR1 amplification has been identified recently as an important therapeutic target in non-small-cell lung cancer (NSCLC), particularly squamous cell carcinoma (SqCC). However, data from previous studies on the clinical implications of FGFR amplification in NSCLC are inconsistent. We evaluated FGFR1 gene copy number (GCN) in 369 cases of surgically resected NSCLC using five previously reported criteria and investigated associations between clinicopathologic parameters and FGFR1 amplification. FGFR1 amplification was found in 32/369 (8.7 %) of NSCLC and was more frequent in SqCC (18.0 % in SqCC, 3.0 % in adenocarcinoma; p < 0.001) and in smokers (p < 0.001). On univariate analysis, FGFR1 amplification was significantly associated with shorter overall survival (OS, 58.6 vs 80.0 months; p = 0.033) and shorter disease-free survival (DFS, 58.5 vs 80.0 months; p = 0.042) in patients with SqCC, but this was not statistically significant on multivariate analysis (OS: hazard ratio [HR] = 1.79, 95 % confidence interval [CI] = 0.83-3.87, p = 0.139; DFS: HR = 1.73, 95 % CI = 0.93-3.21, p = 0.081). The correlation between FGFR1 amplification and protein expression was poor (rho = 0.08; p = 0.123). These results suggest that FGFR1 amplification is associated with smoking history and squamous cell carcinoma histology and might indicate poor prognosis.

Authors+Show Affiliations

Department of Pathology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Jung-gu, Daegu, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25086725

Citation

Seo, An Na, et al. "FGFR1 Amplification Is Associated With Poor Prognosis and Smoking in Non-small-cell Lung Cancer." Virchows Archiv : an International Journal of Pathology, vol. 465, no. 5, 2014, pp. 547-58.
Seo AN, Jin Y, Lee HJ, et al. FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. Virchows Arch. 2014;465(5):547-58.
Seo, A. N., Jin, Y., Lee, H. J., Sun, P. L., Kim, H., Jheon, S., Kim, K., Lee, C. T., & Chung, J. H. (2014). FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. Virchows Archiv : an International Journal of Pathology, 465(5), 547-58. https://doi.org/10.1007/s00428-014-1634-2
Seo AN, et al. FGFR1 Amplification Is Associated With Poor Prognosis and Smoking in Non-small-cell Lung Cancer. Virchows Arch. 2014;465(5):547-58. PubMed PMID: 25086725.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. AU - Seo,An Na, AU - Jin,Yan, AU - Lee,Hee Jin, AU - Sun,Ping-Li, AU - Kim,Hyojin, AU - Jheon,Sanghoon, AU - Kim,Kwhanmien, AU - Lee,Choon-Taek, AU - Chung,Jin-Haeng, Y1 - 2014/08/03/ PY - 2014/03/20/received PY - 2014/07/10/accepted PY - 2014/07/09/revised PY - 2014/8/4/entrez PY - 2014/8/5/pubmed PY - 2014/12/23/medline SP - 547 EP - 58 JF - Virchows Archiv : an international journal of pathology JO - Virchows Arch VL - 465 IS - 5 N2 - FGFR1 amplification has been identified recently as an important therapeutic target in non-small-cell lung cancer (NSCLC), particularly squamous cell carcinoma (SqCC). However, data from previous studies on the clinical implications of FGFR amplification in NSCLC are inconsistent. We evaluated FGFR1 gene copy number (GCN) in 369 cases of surgically resected NSCLC using five previously reported criteria and investigated associations between clinicopathologic parameters and FGFR1 amplification. FGFR1 amplification was found in 32/369 (8.7 %) of NSCLC and was more frequent in SqCC (18.0 % in SqCC, 3.0 % in adenocarcinoma; p < 0.001) and in smokers (p < 0.001). On univariate analysis, FGFR1 amplification was significantly associated with shorter overall survival (OS, 58.6 vs 80.0 months; p = 0.033) and shorter disease-free survival (DFS, 58.5 vs 80.0 months; p = 0.042) in patients with SqCC, but this was not statistically significant on multivariate analysis (OS: hazard ratio [HR] = 1.79, 95 % confidence interval [CI] = 0.83-3.87, p = 0.139; DFS: HR = 1.73, 95 % CI = 0.93-3.21, p = 0.081). The correlation between FGFR1 amplification and protein expression was poor (rho = 0.08; p = 0.123). These results suggest that FGFR1 amplification is associated with smoking history and squamous cell carcinoma histology and might indicate poor prognosis. SN - 1432-2307 UR - https://www.unboundmedicine.com/medline/citation/25086725/FGFR1_amplification_is_associated_with_poor_prognosis_and_smoking_in_non_small_cell_lung_cancer_ DB - PRIME DP - Unbound Medicine ER -